Literature DB >> 15899773

Studies of the site and distribution of CD34+ cells in idiopathic myelofibrosis.

Hongyu Ni1, Giovanni Barosi, Damiano Rondelli, Ronald Hoffman.   

Abstract

The frequency and distribution of CD34+ cells in the bone marrow (BM) of patients with idiopathic myelofibrosis (IM) were determined using an immunohistochemical technique. The percentage and absolute number of circulating CD34+ cells were enumerated. Patients with IM exhibited a continuum of number of BM CD34+ cells ranging from 1 to 85 per 5 mm(2). The frequency of BM CD34+ cells was inversely related to the number of circulating CD34+ cells. The BM biopsy specimens obtained from 4 patients with IM who underwent allogeneic stem cell transplantation were examined sequentially. Quantitative measurement revealed that the reticulin fiber volume was progressively reduced after allogeneic stem cell transplantation. All 4 patients had normocellular marrow with normal numbers of BM CD34+ cells after transplantation. These findings suggest that the BM fibrosis and abnormal hematopoietic stem cell distribution in patients with IM is a consequence of the progeny of a malignant hematopoietic stem cell clone.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15899773     DOI: 10.1309/7A5J-U9KJ-K89V-QPH9

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  5 in total

1.  Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.

Authors:  John Mascarenhas; Mark L Heaney; Vesna Najfeld; Elizabeth Hexner; Omar Abdel-Wahab; Raajit Rampal; Farhad Ravandi; Bruce Petersen; Gail Roboz; Eric Feldman; Nikolai Podoltsev; Dan Douer; Ross Levine; Martin Tallman; Ronald Hoffman
Journal:  Leuk Res       Date:  2012-08-28       Impact factor: 3.156

Review 2.  Rational therapeutic options for patients with myeloproliferative neoplasms.

Authors:  Ronald Hoffman
Journal:  Trans Am Clin Climatol Assoc       Date:  2011

3.  Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells.

Authors:  Min Lu; Lijuan Xia; Yen-Chun Liu; Tsivia Hochman; Laetizia Bizzari; Daniel Aruch; Jane Lew; Rona Weinberg; Judith D Goldberg; Ronald Hoffman
Journal:  Blood       Date:  2015-05-28       Impact factor: 22.113

4.  Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease.

Authors:  Anna Rita Migliaccio; Fabrizio Martelli; Maria Verrucci; Giovanni Migliaccio; Alessandro Maria Vannucchi; Hongyu Ni; Mingjiang Xu; Yi Jiang; Betty Nakamoto; Thalia Papayannopoulou; Ronald Hoffman
Journal:  Exp Hematol       Date:  2008-02       Impact factor: 3.084

5.  MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.

Authors:  Damiano Rondelli; Judith D Goldberg; Luis Isola; Leah S Price; Tsiporah B Shore; Michael Boyer; Andrea Bacigalupo; Alessandro Rambaldi; Marco Scarano; Rebecca B Klisovic; Vikas Gupta; Bjorn Andreasson; John Mascarenhas; Meir Wetzler; Alessandro M Vannucchi; Josef T Prchal; Vesna Najfeld; Attilio Orazi; Rona S Weinberg; Crystal Miller; Giovanni Barosi; Lewis R Silverman; Giuseppe Prosperini; Roberto Marchioli; Ronald Hoffman
Journal:  Blood       Date:  2014-06-24       Impact factor: 22.113

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.